ISSN: 1859 - 2872
Impact of Ganfort on intraocular pressure changing in angle open primary glaucoma
Main Article Content
Keywords
Abstract
Objective: To evaluate the effectiveness of Ganfort on intraocular pressure (IOP) in angle open primary glaucoma (AOPG). Subject and method: The study was conducted in a prospective, clinical trial using Ganfort (Timolol maleate 0.5% - bimatobrost 0.03%) once daily at 7am. Studies performed on open-angle glaucoma was being treated with β-blockers or prostaglandin but with ocular pressure above 21mmHg; or was being treated with other fix combination glaucoma medications but IOP had not reached the target IOP. Result: The successful result was 84.44%. The mean follow-up was 2 weeks 16.21 ± 3.154mmHg, after 3 months of treatment 14.57 ± 2.535mmHg. The average IOP reduced glaucoma was 13.58mmHg, equivalent to 47.44%, stable through treatment months. Daily intraocular pressure fluctuations of 1.348 - 1.437mmHg was within normal physiological limits. Conclusion: Ganfort is effective in lowering intraocular pressure and reduce IOP fluctuation during the day.
Article Details
References
2. Curran MP and Orman JS (2009) Bimatoprost/timolol A review of its use in Glaucoma and ocular hypertension. Drugs Aging 26(2): 169-184.
3. Hommer A et al (2007) A double-masked, randomized, parallel comparision of a fixed combination of bimatoprost 0.03%/ timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. European Journal of Ophthalmology 17: 53-62.
4. Feuerhake C, Buchholz P, Friedemann K (2009) Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: Multicenter, open-label observational study. Current Medical Research Opinion 25.
Article Sidebar
